These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 24439555)

  • 1. The cytokine model of schizophrenia: emerging therapeutic strategies.
    Girgis RR; Kumar SS; Brown AS
    Biol Psychiatry; 2014 Feb; 75(4):292-299. PubMed ID: 24439555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.
    Poels EM; Kegeles LS; Kantrowitz JT; Slifstein M; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
    Mol Psychiatry; 2014 Jan; 19(1):20-9. PubMed ID: 24166406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
    Gomes FV; Grace AA
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiome and adaptive immunity in schizophrenia.
    Agorastos A; Bozikas VP
    Psychiatriki; 2019; 30(3):189-192. PubMed ID: 31685450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?
    Kato TA; Monji A; Mizoguchi Y; Hashioka S; Horikawa H; Seki Y; Kasai M; Utsumi H; Kanba S
    Mini Rev Med Chem; 2011 Jun; 11(7):565-74. PubMed ID: 21699487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of second-generation antipsychotics monotherapy or combined therapy in cytokine, lymphocyte subtype, and thyroid antibodies for schizophrenia: a retrospective study.
    Guo X; Kong L; Wen Y; Chen L; Hu S
    BMC Psychiatry; 2024 Oct; 24(1):695. PubMed ID: 39415112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis.
    Yilmaz Z; Zai CC; Hwang R; Mann S; Arenovich T; Remington G; Daskalakis ZJ
    Schizophr Res; 2012 Sep; 140(1-3):214-20. PubMed ID: 22795368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?
    Ansari Z; Pawar S; Seetharaman R
    Postgrad Med; 2022 Mar; 134(2):187-199. PubMed ID: 34766870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate and dopamine in schizophrenia: an update for the 21st century.
    Howes O; McCutcheon R; Stone J
    J Psychopharmacol; 2015 Feb; 29(2):97-115. PubMed ID: 25586400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
    Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
    Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia.
    Monji A; Kato T; Kanba S
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):257-65. PubMed ID: 19579286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
    Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.
    Al-Dujaili AH; Mousa RF; Al-Hakeim HK; Maes M
    Schizophr Bull; 2021 Mar; 47(2):530-541. PubMed ID: 32971537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines in schizophrenia and the effects of antipsychotic drugs.
    Drzyzga L; Obuchowicz E; Marcinowska A; Herman ZS
    Brain Behav Immun; 2006 Nov; 20(6):532-45. PubMed ID: 16580814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.
    de Bartolomeis A; Iasevoli F; Tomasetti C; Buonaguro EF
    Mol Neurobiol; 2015 Dec; 52(3):1771-1790. PubMed ID: 25394379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR/mTOR inflammatory signaling pathway: novel insight for the treatment of schizophrenia.
    Lashgari NA; Roudsari NM; Shamsnia HS; Shayan M; Momtaz S; Abdolghaffari AH
    Can J Physiol Pharmacol; 2024 Mar; 102(3):150-160. PubMed ID: 37955633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.
    Demjaha A; Egerton A; Murray RM; Kapur S; Howes OD; Stone JM; McGuire PK
    Biol Psychiatry; 2014 Mar; 75(5):e11-3. PubMed ID: 23890739
    [No Abstract]   [Full Text] [Related]  

  • 19. Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review.
    de Bartolomeis A; Barone A; Vellucci L; Mazza B; Austin MC; Iasevoli F; Ciccarelli M
    Mol Neurobiol; 2022 Oct; 59(10):6460-6501. PubMed ID: 35963926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.
    Perez SM; Lodge DJ
    Drug Des Devel Ther; 2014; 8():887-96. PubMed ID: 25061280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.